l-histidine

Small moleculeexperimental

Histidine is an essential amino acid. L-histidine is converted to histamine by histidine decarboxylase, a pyridoxal 5'-phosphate-dependent enzyme. The copper(II)–l-histidine (1:2 complex at physiological pH) has been widely used in the treatment of Menkes disease (a genetic neurodegenerative disorder that leads to early death in the children due to impaired copper metabolism) and more recent use has been reported in the treatment of infantile hypertrophic cardioencephalomyopathy (a condition caused by mutations in SCO2, a cytochrome c oxidase assembly gene). CUSTODIOL HTK (Histidine-tryptophan-ketoglutarate) Solution is indicated for perfusion and flushing of donor kidneys, liver, and heart prior to removal from the donor or immediately after removal from the donor. — NCATS

Clinical trial activity

12 trials · 14 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 2012 (NCT01681095)

Timeline

2010s

Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Jan 1, 2017
Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Burns (approved 1971)

Studied for

Mechanism of action

ATP phosphoribosyltransferaseINHIBITOR
hisG inhibitor
- ATP phosphoribosyltransferase (hisG) ↗

Chemistry & pharmacology

Loading structure…

SMILES

N[C@@H](CC1=CNC=N1)C(O)=O

Mol. weight: 155.1546 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

h
h
his
his
histidine
histidine
histidine
histidine
histidine
histidine
l-histidin
l-histidin
l-histidine
l-histidine
l-histidine
l-histidine
l-histidine
l-histidine
l-(-)-histidine
l-(-)-histidine
l-(−)-histidine
l-(−)-histidine
(s)-4-(2-amino-2-carboxyethyl)imidazole
(s)-4-(2-amino-2-carboxyethyl)imidazole
(s)-a-amino-1h-imidazole-4-propanoic acid
(s)-a-amino-1h-imidazole-4-propanoic acid
(s)-alpha-amino-1h-imidazole-4-propanoic acid
(s)-alpha-amino-1h-imidazole-4-propanoic acid
(s)-alpha-amino-1h-imidazole-4-propionic acid
(s)-alpha-amino-1h-imidazole-4-propionic acid
(s)-α-amino-1h-imidazole-4-propanoic acid
(s)-α-amino-1h-imidazole-4-propanoic acid

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06377631	N/A	Jun 7, 2024	Eurecat
NCT06414330	N/A	Jun 1, 2024	Assiut University
NCT06169826	Phase 4	Apr 30, 2024	Wake Forest University
NCT05807204	N/A	May 1, 2023	Eurecat
NCT04764383	Phase 2	Jan 1, 2022	University of Miami
NCT04364750	Early Phase 1 (Phase 1)	May 31, 2020	McMaster University
NCT03266965	Phase 1	Mar 23, 2018	Department of Defense, University of Miami
NCT04142294	N/A	Sep 21, 2017	Cornell University
NCT02924935	Early Phase 1 (Phase 1)	Jan 1, 2017	University of Western Ontario
NCT03082716	Phase 2	Sep 19, 2016	King Faisal University
NCT02618824	Phase 2	Dec 1, 2015	University of Indonesia
NCT01681095	Phase 2	Aug 1, 2012	Essential Pharmaceuticals, LLC, Oakland University, United States Army, William Beaumont Hospitals

Showing 12 of 12 trials

Page 1 / 1

Organizations

Research & Development (14)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Eurecat	For profit	2	2	1	2023
University of Miami	Academic/Hospital	2	2	2	2018
Assiut University	Academic/Hospital	1	1	1	2024
Cornell University	Academic/Hospital	1	1	1	2017
Department of Defense	Government	1	0	1	2018
Essential Pharmaceuticals, LLC	For profit	1	0	1	2012
King Faisal University	Academic/Hospital	1	1	1	2016
McMaster University	Academic/Hospital	1	1	1	2020
Oakland University	Academic/Hospital	1	0	1	2012
United States Army	Government	1	0	1	2012
University of Indonesia	Academic/Hospital	1	1	1	2015
University of Western Ontario	Academic/Hospital	1	1	1	2017
Wake Forest University	Academic/Hospital	1	1	1	2024
William Beaumont Hospitals	Academic/Hospital	1	1	1	2012

14 organizations

Page 1 / 1